Top

Gepubliceerd in:

2021 | OriginalPaper | Hoofdstuk

6. Longtumoren

Auteur : J. J. C. Verhoeff, MD PhD

Gepubliceerd in: Radiotherapie bij de oncologische patiënt

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Inhoud – 1 Inleiding – 2 Diagnostiek – 3 Behandeling – 4 Follow-up: toxiciteit en bijwerkingen. Longtumoren vormen in aantal de grootste groep van alle kankersoorten, omdat ze sekseaspecifiek voorkomen. Ongeveer de helft van de longtumoren wordt pas ontdekt in stadium IV, waarbij enkel palliatieve behandeling mogelijk is. Niet-kleincellige longtumoren vormen de grootste subgroep, met chemotherapie, bestraling en immuuntherapie als belangrijkste behandelingen. De PET-CT is belangrijk bij de diagnostiek en bij de planning van radiotherapie. Radiotherapie wordt (stereotactisch) curatief gegeven in plaats van chirurgie in stadium I en II, standaard gefractioneerd gecombineerd met chemotherapie in stadium III en in een kort schema palliatief in stadium IV. Beweging door ademhaling wordt meegenomen in de planning via het ITV-concept of met complexe technieken als gating en breathhold. Acute bijwerkingen van radiotherapie zijn met name vermoeidheid, oesofagitis en hoestklachten. Op lange termijn kan een stralingsfibrose ontstaan, kan de longfunctie beperkter raken en kunnen hart- en vaatziekten optreden. Daarom is protonenbehandeling in goed geselecteerde patiënten waarschijnlijk gerechtvaardigd.

vorige hoofdstuk Tumoren van de tractus digestivus

volgende hoofdstuk Hoofd-halstumoren

Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Brahmer J. Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 Study. J Clin Oncol. 2018;36(17):1675–84. https://www.ncbi.nlm.nih.gov/pubmed/29570421/.CrossRef

Rangachari D, Le Xiuning MD, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy. J Thorac Oncol. 2017;12(11):e175–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659921/.CrossRef

Naruke T. The spread of lung cancer and its relevance to surgery. Nippon Kyobu Geka Gakkai Zasshi. 1967;68:1607–21.

Detterbeck FC. The eighth edition TNM stage classification for lung cancer: what does it mean on main street? J Thorac Cardiovasc Surg. 2018;155(1):356–9. https://www.jtcvs.org/article/S0022-5223(17)32136-0/.CrossRef

Falkson CB, Vella ET, Yu E, El-Mallah M, Mackenzie R, Ellis PM, Ung YC. Radiotherapy with curative intent in patients with early-stage, medically inoperable, non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18(2):105–21. https://www.ncbi.nlm.nih.gov/pubmed/27908621.CrossRef

Tekatli H, Duijm M, Oomen-de Hoop E, Verbakel W, Schillemans W, Slotman BJ, Nuyttens JJ, Senan S. Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors. Int J Radiat Oncol. 2018;100(3):738–47. https://www.ncbi.nlm.nih.gov/pubmed/29413285.CrossRef

Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Bradley JD. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol. 2019;103(5):1077–84. https://www.ncbi.nlm.nih.gov/pubmed/30513377.CrossRef

Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, D’Amico TA. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93(6):1807–12. https://www.ncbi.nlm.nih.gov/pubmed/22632486.CrossRef

Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R; PORT Meta‐analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016;10:CD002142. https://www.ncbi.nlm.nih.gov/pubmed/27727451.

10.

Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer. J Thorac Oncol. 2015;33(25):2727–34. https://www.ncbi.nlm.nih.gov/pubmed/26101240.

11.

NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311(7010):899–909. https://www.ncbi.nlm.nih.gov/pubmed/7580546.CrossRef

12.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50. https://www.ncbi.nlm.nih.gov/pubmed/30280658.

13.

Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–15. https://www.ncbi.nlm.nih.gov/pubmed/29191596.CrossRef

14.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Gandara DR. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018;13(9):1248–68. https://www.ncbi.nlm.nih.gov/pubmed/29885479.CrossRef

15.

Tsao MN, Ven LI, Cheung P, Poon I, Ung Y, Louie AV. Stereotactic body radiation therapy for extracranial oligometastatic non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2020;21(2):95–105. https://www.ncbi.nlm.nih.gov/pubmed/31959533.CrossRef

16.

Slotman BJ, Faivre-Finn C, Van Tinteren H, Keijser A, Praag J, Knegjens J, Hatton M, Van Dam I, Van der Leest A, Reymen B, Stigt J, Senan S. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the Phase III CREST trial. Lung Cancer. 2017;108:150–3. https://www.ncbi.nlm.nih.gov/pubmed/28625628.CrossRef

17.

Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72. https://www.ncbi.nlm.nih.gov/pubmed/17699816.CrossRef

18.

Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467–74. https://www.ncbi.nlm.nih.gov/pubmed/19386548.CrossRef

19.

Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yamamoto N. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71. https://www.ncbi.nlm.nih.gov/pubmed/28343976.CrossRef

20.

Wolthaus JW, Schneider C, Sonke JJ, Van Herk M, Belderbos JS, Rossi MM, Lebesque JV, Damen EM. Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys. 2006;65(5):1560–71. https://www.ncbi.nlm.nih.gov/pubmed/16863933.CrossRef

21.

Higgins KA, O’Connell K, Liu Y, Gillespie TW, McDonald MW, Pillai RN, Patel KR, Patel PR, Robinson CG, Simone CB II, Owonikoko TK, Behera M. National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016;97(1):128–37. https://www.ncbi.nlm.nih.gov/pubmed/27979443.CrossRef

22.

Finazzi T, Palacios MA, Spoelstra FO, Haasbeek CJ, Bruynzeel AM, Slotman BJ, Lagerwaard FJ, Senan S. Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors. Int J Radiat Oncol Biol Phys. 2019;104(4):933–41. https://www.ncbi.nlm.nih.gov/pubmed/30928360.CrossRef

23.

Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Choy H. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706–14. https://www.ncbi.nlm.nih.gov/pubmed/31841363.CrossRef

Titel: Longtumoren
Auteur: J. J. C. Verhoeff, MD PhD
Uitgeverij: Bohn Stafleu van Loghum
Boek: Radiotherapie bij de oncologische patiënt
Print ISBN: 978-90-368-2611-2

Elektronisch ISBN: 978-90-368-2612-9

Copyright: 2021
DOI: https://doi.org/10.1007/16013_2020_17

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen